ReviewFrontiers in immunology2019
Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Preliminary high-dose irradiation of the recipient and associated damage of bone marrow stromal compartment enables bone marrow stroma transplantation.Scientific reports · 2025Article
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- [Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?Transplantation direct · 2025Article
- Effect of Haplo-Allogeneic Hematopoietic Stem Cell Transplantation Timing on Patients with Severe Aplastic Anemia Without Histocompatible Matched Sibling Donor.Journal of blood medicine · 2025Article
- Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.Bone marrow transplantation · 2024Article
- The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults.Frontiers in immunology · 2024Review
- ABO incompatibility haploidentical peripheral blood stem cell transplantation combined with a single cord blood unit for severe aplastic anemia patients.SAGE open medicine · 2024Article
- After Bone Marrow Transplantation, the Cell-Intrinsic Th2 Pathway Promotes Recipient T Lymphocyte Survival and Regulates Graft-versus-Host Disease.ImmunoHorizons · 2023Article
- Unrelated umbilical cord blood can improve the prognosis of haploidentical hematopoietic stem cell transplantation.Stem cell research & therapy · 2022Article
- Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022Review
- Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.Oncology and therapy · 2022Review
- A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.International journal of hematology · 2022Article
- Rapamycin Promotes the Expansion of Myeloid Cells by Increasing G-CSF Expression in Mesenchymal Stem Cells.Frontiers in cell and developmental biology · 2022Article
- Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation.Frontiers in immunology · 2022Article
- T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy.Frontiers in pediatrics · 2022Review
- Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-Therapeutic advances in hematology · 2022Article
- Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies.Bone marrow transplantation · 2021Review
- Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.Current medical science · 2021Article
- Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.Bone marrow transplantation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been successfully used for stem cell mobilization and T cell immune tolerance induction. The establishment of G-CSF-primed unmanipulated haploidentical blood and marrow transplantation (The Beijing Protocol) has achieved outcomes for the treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia with haploidentical allografts comparable to those of human leukocyte antigen (HLA)-matched sibling donor transplantation. Currently, G-CSF-mobilized bone marrow and/or peripheral blood stem cell sources have been widely used in unmanipulated haploidentical transplant settings. In this review, we summarize the roles of G-CSF in inducing T cell immune tolerance. We discuss the recent advances in the Beijing Protocol, mainly focusing on strategies that have been used to improve transplant outcomes in cases of poor graft function, virus infections, and relapse. The application of G-CSF-primed allografts in other haploidentical modalities is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.